VivoSeq
Neurology

Amyotrophic Lateral Sclerosis (ALS)

6

Pipeline Programs↗

8

Active Trials↗

3

Companies Involved↗

Amyotrophic Lateral Sclerosis (ALS) is an early-stage landscape with 6 programs across 3 companies. The most active players are Novartis, Regeneron, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Regeneron logo

Regeneron

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Recruiting7 · 88%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Pilot Trial to Investigate the Safety and Efficacy of Intestinal Microbiome Transplant (MTT) in People With Amyotrophic Lateral Sclerosis
Recruiting·DDuke University·Preclinical·NCT07017946·20 enrolled
Identification of Early Markers for ALS
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Preclinical·NCT07213440·60 enrolled
High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Recruiting·UUniversidade Federal do Rio Grande do Norte·Preclinical·NCT06719947·80 enrolled
A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT07071935·48 enrolled
Healing ALS Registry Observational Study (HAROS)
Recruiting·HHealing Advocates Registry and Ministry·N/A·NCT07233148·1,000 enrolled
A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
Recruiting·NNura Bio·Preclinical·NCT07369076·80 enrolled
First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations
Recruiting·Regeneron logoRegeneron·Preclinical·NCT06351592·54 enrolled
A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT06643481·251 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)